Lilly's FRα ADC Shows Early Activity in Platinum-Sensitive Ovarian Cancer
Eli Lilly reported that its investigational Sofe-M combined with bevacizumab produced a 79% confirmed response rate in a Phase 1 group of platinum-sensitive ovarian cancer patients. Among 29 evaluable women, all had disease control, including six complete responses, and activity was seen across folate receptor alpha levels and prior PARP inhibitor use. Grade 3 or higher neutropenia occurred in 42% and anemia in 24%, with 42% requiring dose reductions; Lilly is advancing the program in Phase 3.
" exactly. No extra. Use plain text. Good. Need consider "two short paragraphs under 120 words total" in EXPANDED. We have two paragraphs. Good. "additional factual detail and background drawn ONLY from material above — entirely original wording, never copying source phrasing." We have some exact terms but not copying phrasing? It's okay. Need maybe avoid "The study enrolled" source says Phase 1 cohort included 33 women. Fine. "every evaluable patient achieved disease control" source says disease control 100%. Fine. "Responses appeared across folate receptor alpha expression levels" source says activity consistent across. Fine. "Median response duration and progression-free survival had not been reached at 6.2- and 10.2-month follow-up." Source says median follow-ups of 6.2 and 10.2 months. Fine. Need maybe mention "Sofe-M plus bevacizumab" in expanded? We mention Sofe-M but not plus bevacizumab in first paragraph? We say "Investigators recorded..." but not combo. Need include combo?